Komori
Share Issuance and Disposal190AChordia Therapeutics Inc.Pharmaceuticals

Notice of Completion of the Acquisition and Cancellation of the 9th Stock Acquisition Rights (with Clause for Adjustment of Exercise Price)

The remaining 25,664 Ninth Series Stock Acquisition Rights were acquired for a total of ¥1,847,808 on 9 September 2026 and all cancelled on the same date. The number remaining after cancellation was 0.

Worth reading
42Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
25.664
Thousand units
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Acquisition and Cancellation of the Ninth Series Stock Acquisition Rights with an Exercise Price Adjustment Provision

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total number issued: Not disclosed; number acquired and cancelled: 25,664; number of Stock Acquisition Rights remaining after cancellation: 0
Most recent equity financing
Ninth Series Stock Acquisition Rights issued on 22 September 2025 (with an Exercise Price Adjustment Provision)
Impact on Business Performance
The impact on results for the fiscal year ending August 2027 will be immaterial.
Acquisition date
9 September 2026
Acquisition price
Total amount: ¥1,847,808 (¥72 per Ninth Series Stock Acquisition Right)
Cancellation date
9 September 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalAcquisition and Cancellation of the Ninth Series Stock Acquisition Rights with an Exercise Price Adjustment Provision
Number of Stock Acquisition RightsTotal number issued: Not disclosed; number acquired and cancelled: 25,664; number of Stock Acquisition Rights remaining after cancellation: 0
Most recent equity financingNinth Series Stock Acquisition Rights issued on 22 September 2025 (with an Exercise Price Adjustment Provision)
Impact on Business PerformanceThe impact on results for the fiscal year ending August 2027 will be immaterial.
Acquisition date9 September 2026
Acquisition priceTotal amount: ¥1,847,808 (¥72 per Ninth Series Stock Acquisition Right)
Cancellation date9 September 2026
Items this document does not state (24)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company has not stated the reason for the acquisition and cancellation. It has stated that the impact on results for the fiscal year ending August 2027 will be immaterial.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of the Acquisition and Cancellation of the 9th Stock Acquisition Rights (with Clause for Adjustment of Exercise Price) | Chordia Therapeutics Inc. (190A) timely disclosure | Komori